Beractant
Clinical data
Trade namesSurvanta, Alveofact
AHFS/Drugs.comMonograph
Routes of
administration		Endotracheal
ATC code
  • None
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
 ☒NcheckY (what is this?)  (verify)

Beractant, also known by the trade name of Survanta, is a modified bovine pulmonary surfactant containing bovine lung extract (phospholipids, neutral lipids, fatty acids, and bovine surfactant proteins), to which synthetic DPPC, tripalmitin and palmitic acid are added. The composition provides 25 mg/mL phospholipids, 0.5 to 1.75 mg/mL triglycerides, 1.4 to 3.5 mg/mL free fatty acids, and <1.0 mg/mL total surfactant proteins.[1] As an intratracheal suspension, it can be used for the prevention and treatment of neonatal respiratory distress syndrome.[2] Survanta is manufactured by Abbvie.

Generic form

Beraksurf is generic form of Survanta (Beractant) which is manufacturing by Tekzima.

References

  1. ^ Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A, et al. (April 2005). "A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants". Pediatrics. 115 (4): 1018–29. doi:10.1542/peds.2004-2183. PMID 15805380. S2CID 40458323.
  2. ^ Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Gunkel JH (January 1998). "Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group". The Journal of Pediatrics. 132 (1): 40–7. doi:10.1016/S0022-3476(98)70482-2. PMID 9469998.

External links


More
Categories